Effects of substance use disorder on treatment process and outcome in a ten-session psychiatric treatment for borderline personality disorder

Louise Penzenstadler, Stéphane Kolly, Stéphane Rothen, Yasser Khazaal, Ueli Kramer, Louise Penzenstadler, Stéphane Kolly, Stéphane Rothen, Yasser Khazaal, Ueli Kramer

Abstract

Background: Dual diagnosis is common in Borderline Personality Disorder (BPD), one of the most common being Substance Use Disorder (SUD). Previous studies have shown that general psychiatric management (GPM) was effective in reducing borderline symptoms. In the present study, we tested whether the short GPM was as effective in the BPD + SUD as in the BPD group.

Methods: We analysed a group of 99 patients presenting a BPD. 51 of these patients presented a SUD. The BPD group and the BPD + SUD group received a manual-based short variant of the GPM treatment. Previous studies have shown that a 10-session version of GPM was effective in reducing borderline symptoms at the end of the treatment (Psychother Psychosom 83:176-86, 2014).

Results: We found no significant difference in the reduction of general symptoms, which diminished in both groups. The specific borderline symptoms were also reduced in both groups, but there was a slightly higher reduction of the borderline symptoms in the SUD group. The therapeutic alliance progressed positively in all groups. Moreover, the alliance increased more over time in the SUD group.

Conclusion: The short variant of GPM seems to be effective in BPD treatment independently from the presence of SUD. Therefore, this treatment could be an effective entry-level treatment for patients with dual diagnosis as well as patients with BPD only. Further studies are needed to confirm efficacy and long-term outcome.

Trial registration: The trial was registered at ClinicalTrial.gov (identifier NCT01896024 ).

Conflict of interest statement

Ethics approval and consent to participate

The study was formally approved by the relevant Ethics Board (identifier 254/08) and research committee. The participants gave a written informed consent to take part in the trial and to publish. The trial was registered at ClinicalTrial.gov (identifier NCT01896024).

Consent for publication

All participants consented to their data being included in publications, provided that identifying information was not published.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Adjusted change of the BSL from the linear mixed-effects models

References

    1. Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline diagnosis I: psychopathology, comorbidity, and personaltity structure. Biol Psychiatry. 2002;51(12):936–950. doi: 10.1016/S0006-3223(02)01324-0.
    1. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2011;377(9759):74–84. doi: 10.1016/S0140-6736(10)61422-5.
    1. Trull TJ, Sher KJ, Minks-Brown C, Durbin J, Burr R. Borderline personality disorder and substance use disorders: a review and integration. Clin Psychol Rev. 2000;20(2):235–253. doi: 10.1016/S0272-7358(99)00028-8.
    1. Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71–80. doi: 10.1001/archpsyc.1997.01830130077015.
    1. Weiss RD, Mirin SM, Griffin ML, Gunderson JG, Hufford C. Personality disorders in cocaine dependence. Compr Psychiatry. 1993;34(3):145–149. doi: 10.1016/0010-440X(93)90040-B.
    1. Preuss UW, Johann M, Fehr C, Koller G, Wodarz N, Hesselbrock V, et al. Personality disorders in alcohol-dependent individuals: relationship with alcohol dependence severity. Eur Addict Res. 2009;15(4):188–195. doi: 10.1159/000228929.
    1. Kienast T, Stoffers J, Bermpohl F, Lieb K. Borderline personality disorder and comorbid addiction: epidemiology and treatment. Dtsch Arztebl Int. 2014;111(16):280.
    1. Barber JP, Frank A, Weiss RD, Blaine J, Siqueland L, Moras K, et al. Prevalence and correlates of personality disorder diagnoses among cocaine dependent outpatients. J Personal Disord. 1996;10(4):297. doi: 10.1521/pedi.1996.10.4.297.
    1. Langås A-M, Malt UF, Opjordsmoen S. In-depth study of personality disorders in first-admission patients with substance use disorders. BMC psychiatry. 2012;12(1):1. doi: 10.1186/1471-244X-12-180.
    1. Bowden-Jones O, Iqbal MZ, Tyrer P, Seivewright N, Cooper S, Judd A, et al. Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction. 2004;99(10):1306–1314. doi: 10.1111/j.1360-0443.2004.00813.x.
    1. Darke S, Ross J, Williamson A, Teesson M. The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction. 2005;100(8):1121–1130. doi: 10.1111/j.1360-0443.2005.01123.x.
    1. McMain S, Ellery M. Screening and assessment of personality disorders in addiction treatment settings. Int J Ment Heal Addict. 2008;6(1):20–31. doi: 10.1007/s11469-007-9093-5.
    1. Stoffers-Winterling JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012, Issue 8. Art. No.: CD005652. doi:10.1002/14651858.CD005652.pub2.
    1. Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, et al. Treatment utilization by patients with personality disorders. Am J Psychiatr. 2001;158(2):295–302. doi: 10.1176/appi.ajp.158.2.295.
    1. Barnicot K, Katsakou C, Bhatti N, Savill M, Fearns N, Priebe S. Factors predicting the outcome of psychotherapy for borderline personality disorder: a systematic review. Clin Psychol Rev. 2012;32(5):400–412. doi: 10.1016/j.cpr.2012.04.004.
    1. Lee NK, Cameron J, Jenner L. A systematic review of interventions for co-occurring substance use and borderline personality disorders. Drug and alcohol review. 2015;34(6):663–672. doi: 10.1111/dar.12267.
    1. Gainey RR, Wells EA, Hawkins JD, Catalano RF. Predicting treatment retention among cocaine users. Int J Addict. 1993;28(6):487–505. doi: 10.3109/10826089309039643.
    1. Stark MJ, Campbell BK. Personality, drug use, and early attrition from substance abuse treatment. The American journal of drug and alcohol abuse. 1988;14(4):475–485. doi: 10.3109/00952998809001565.
    1. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. The American journal of drug and alcohol abuse. 1991;17(3):229–247. doi: 10.3109/00952999109027549.
    1. Carroll KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow P, Bisighini RM, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994;51(3):177–187. doi: 10.1001/archpsyc.1994.03950030013002.
    1. Barber JP, Gallop R, Crits-Christoph P, Frank A, Thase ME, Weiss RD, et al. The role of therapist adherence, therapist competence, and alliance in predicting outcome of individual drug counseling: results from the National Institute Drug Abuse Collaborative Cocaine Treatment Study. Psychother Res. 2006;16(02):229–240. doi: 10.1080/10503300500288951.
    1. Laaksonen MA, Knekt P, Lindfors O. Psychological predictors of the recovery from mood or anxiety disorder in short-term and long-term psychotherapy during a 3-year follow-up. Psychiatry Res. 2013;208(2):162–173. doi: 10.1016/j.psychres.2012.09.053.
    1. Ventegodt S, Thegler S, Andreasen T, Struve F, Enevoldsen L, Bassaine L, et al. Clinical holistic medicine (mindful, short-term psychodynamic psychotherapy complemented with bodywork) in the treatment of experienced physical illness and chronic pain. Sci World J. 2007;7:310–316. doi: 10.1100/tsw.2007.68.
    1. Gunderson JG. Handbook of good psychiatric management for borderline personality disorder: American psychiatric pub. 2014.
    1. McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatr. 2012;169(6):650–661. doi: 10.1176/appi.ajp.2012.11091416.
    1. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatr. 2009;166(12):1355–1364. doi: 10.1176/appi.ajp.2009.09040539.
    1. Raven MC, Carrier ER, Lee J, Billings JC, Marr M, Gourevitch MN. Substance use treatment barriers for patients with frequent hospital admissions. J Subst Abus Treat. 2010;38(1):22–30. doi: 10.1016/j.jsat.2009.05.009.
    1. Skule C, Berge T, Eilertsen E, Ulleberg P, Dallavara Lending H, Egeland J, et al. Levels of alcohol use and depression severity as predictors of missed therapy sessions in cognitive behavioural psycho-educational group treatment for depression. Addiction research & theory. 2016:1–6.
    1. Paris J. Stepped care: an alternative to routine extended treatment for patients with borderline personality disorder. Psychiatr Serv. 2013;
    1. Chanen AM, Berk M, Thompson K. Integrating early intervention for borderline personality disorder and mood disorders. Harvard review of psychiatry. 2016;
    1. Choi-Kain LW, Albert EB, Gunderson JG. Evidence-based treatments for borderline personality disorder: implementation, integration, and stepped care. Harvard Review of Psychiatry. 2016;24(5):342–356. doi: 10.1097/HRP.0000000000000113.
    1. Black D, Allen J, St John D, Pfohl B, McCormick B, Blum N. Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study. Acta Psychiatr Scand. 2009;120(1):53–61. doi: 10.1111/j.1600-0447.2008.01340.x.
    1. Gunderson JG. The emergence of a generalist model to meet public health needs for patients with borderline personality disorder. Am J Psychiatr. 2016;173(5):452–458. doi: 10.1176/appi.ajp.2015.15070885.
    1. Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Personal Disord. 2014;28(5):734–750. doi: 10.1521/pedi_2012_26_093.
    1. Van Asselt A, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. European Psychiatry. 2007;22(6):354–361. doi: 10.1016/j.eurpsy.2007.04.001.
    1. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse collaborative cocaine treatment study. Arch Gen Psychiatry. 1999;56(6):493–502. doi: 10.1001/archpsyc.56.6.493.
    1. Siqueland L, Crits-Christoph P, Gallop R, Barber JP, Griffin ML, Thase ME, et al. Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. Am J Addict. 2002;11(1):24–40. doi: 10.1080/10550490252801611.
    1. Gunderson JG, Links P. The borderline diagnosis. Borderline personality disorder A clinical guide. 2008. pp. 1–28.
    1. Kramer U, Berger T, Kolly S, Marquet P, Preisig M, de Roten Y, et al. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. J Nerv Ment Dis. 2011;199(4):244–250. doi: 10.1097/NMD.0b013e3182125d19.
    1. Kramer U, Kolly S, Berthoud L, Keller S, Preisig M, Caspar F, et al. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom. 2014;83(3):176–186. doi: 10.1159/000358528.
    1. Caspar F. Plan analysis; in Eells TD (ed): Handbook of psychotherapy case formulation. New York: Guilford Press. 2007;2:221–89.
    1. Kolly S, Despland J-N, de Roten Y, Marquet P, Kramer U. Therapist adherence to good psychiatric practice in a short-term treatment for borderline personality disorder. J Nerv Ment Dis. 2016;204(7):489–93.
    1. First MB, Gibbon M. The structured clinical interview for DSM-IV Axis I disorders (SCID-I) and the structured clinical interview for DSM-IV Axis II disorders (SCID-II) 2004.
    1. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The MINI international neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European psychiatry. 1997;12(5):224–231. doi: 10.1016/S0924-9338(97)83296-8.
    1. Lambert M, Morton J, Hatfield D, Harmon C, Hamilton S, Reid R, et al. & Burlingame, GM (2004). Administration and scoring manual for the Outcome Questionnaire.45.
    1. Emond C, Savard K, Lalande G, Boisvert N, Boutin M, Simard V, editors. Propriétés psychométriques de la Mesure de l’Impact (MI-45), version francophone du Outcome Questionnaire-45 (OQ-45.2)[Psychometric characteristics of the OQ-45, French Version]. American College of Foot and Ankle Surgeons conference, Montreal, QC; 2004.
    1. Bohus M, Kleindienst N, Limberger MF, Stieglitz R-D, Domsalla M, Chapman AL, et al. The short version of the borderline symptom list (BSL-23): development and initial data on psychometric properties. Psychopathology. 2008;42(1):32–39. doi: 10.1159/000173701.
    1. Horvath AO, Greenberg LS. Development and validation of the working alliance inventory. J Couns Psychol. 1989;36(2):223. doi: 10.1037/0022-0167.36.2.223.
    1. Corbière M, Bisson J, Lauzon S, Ricard N. Factorial validation of a French short-form of the working alliance inventory. Int J Methods Psychiatr Res. 2006;15(1):36–45. doi: 10.1002/mpr.27.
    1. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Law-rence Erlbaum Associates. Inc, Publishers; 1988.
    1. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982:963–74.
    1. McCulloch CE, Neuhaus JM. Generalized linear mixed models: Wiley online Library. 2001.
    1. Team RC . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. p. 2014.
    1. Team RC. Package "nlme" CRAN. 2017; Retrieved from . Accessed May 2017.
    1. Barber JP, Luborsky L, Gallop R, Crits-Christoph P, Frank A, Weiss RD, et al. Therapeutic alliance as a predictor of outcome and retention in the National Institute on Drug Abuse collaborative cocaine treatment study. J Consult Clin Psychol. 2001;69(1):119. doi: 10.1037/0022-006X.69.1.119.
    1. Penzenstadler L, Machado A, Thorens G, Zullino D, Khazaal Y. Effect of case management interventions for patients with substance use disorders: a systematic review. Frontiers in psychiatry. 2017;8

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe